Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trial.
Radiother OncolMay 14, 2026 (epub)
Monique C de Jong, Andrew J Hope, José S A Belderbos et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I trial evaluated the safety of combining simultaneous stereotactic body radiotherapy (SBRT) with concurrent cisplatin in 15 patients with stage III non-small cell lung cancer (NSCLC). The study found no dose-limiting toxicities, with a maximum mean lung dose of 19.1 Gy, and achieved high local and regional control rates of 93%.
Key findings
- No dose-limiting toxicity was observed with a maximum treated mean lung dose of 19.1 Gy.
- The most common Grade 1-2 toxicities included radiation pneumonitis in 7 patients and rib fractures in 6 patients.
- Local and regional control rates were both 93%, although 73% of patients developed progressive disease at distant sites.
Why it matters
The findings suggest that combining SBRT with concurrent chemotherapy may enhance local and regional control in stage III NSCLC, providing a potential treatment strategy that minimizes severe toxicities.